Literature DB >> 22445773

Are "bath salts" the next generation of stimulant abuse?

Gerald Scott Winder1, Nathan Stern, Avinash Hosanagar.   

Abstract

"Bath salts" are stimulants with high abuse potential that are known to contain agents such as 3,4-methylenedioxypyrovalerone and 4-methylmethcathinone (mephedrone). They are marketed locally and through online retailers as legitimate products in order to evade legal control and facilitate widespread distribution. They have been present in Europe since 2007 but are now becoming a burgeoning presence in American hospitals. Though preliminary efforts are underway in the United States to restrict their usage and distribution, there remains a general unawareness on the part of physicians regarding the drugs' physiological effects. While they mimic the effects of other known stimulants, they are not detected on standard urine screens. We present a clinical case that illustrates a typical pattern of usage along with a description of their basic chemistry, appearance, methods of delivery, withdrawal and intoxication characteristics, treatment recommendations, and areas for further research.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22445773     DOI: 10.1016/j.jsat.2012.02.003

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  7 in total

1.  Synthetic cathinones and their rewarding and reinforcing effects in rodents.

Authors:  Lucas R Watterson; M Foster Olive
Journal:  Adv Neurosci (Hindawi)       Date:  2014-06-04

Review 2.  The Bridge Between Classical and "Synthetic"/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective.

Authors:  Laura Orsolini; Stefania Chiappini; Duccio Papanti; Domenico De Berardis; John M Corkery; Fabrizio Schifano
Journal:  Front Psychiatry       Date:  2019-11-20       Impact factor: 4.157

3.  Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats.

Authors:  C T Bauer; M L Banks; B E Blough; S S Negus
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

4.  Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays.

Authors:  Matthew D Krasowski; Sean Ekins
Journal:  J Cheminform       Date:  2014-05-10       Impact factor: 5.514

Review 5.  Novel Psychoactive Substances-Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs.

Authors:  Zurina Hassan; Oliver G Bosch; Darshan Singh; Suresh Narayanan; B Vicknasingam Kasinather; Erich Seifritz; Johannes Kornhuber; Boris B Quednow; Christian P Müller
Journal:  Front Psychiatry       Date:  2017-08-18       Impact factor: 4.157

6.  Behavioural, Pharmacokinetic, Metabolic, and Hyperthermic Profile of 3,4-Methylenedioxypyrovalerone (MDPV) in the Wistar Rat.

Authors:  Rachel R Horsley; Eva Lhotkova; Katerina Hajkova; Barbara Feriancikova; Michal Himl; Martin Kuchar; Tomas Páleníček
Journal:  Front Psychiatry       Date:  2018-04-24       Impact factor: 4.157

7.  The Designer Drug 3-Fluoromethcathinone Induces Oxidative Stress and Activates Autophagy in HT22 Neuronal Cells.

Authors:  Kamila Siedlecka-Kroplewska; Agata Wrońska; Grzegorz Stasiłojć; Zbigniew Kmieć
Journal:  Neurotox Res       Date:  2018-04-14       Impact factor: 3.911

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.